Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2014.07.054 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of Sirolimus Use With Risk for Skin Cancer in a Mixed-Organ Cohort of Solid-Organ Transplant Recipients With a History of Cancer.
JAMA Dermatol
May 2016
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Importance: Solid-organ transplant recipients (OTRs) are at an increased risk for skin cancer. Prior studies have demonstrated a reduced incidence of skin cancer in renal OTRs treated with sirolimus. However, little information exists on the use of sirolimus for the prevention of skin cancer in nonrenal OTRs or those already diagnosed as having a posttransplant cancer.
View Article and Find Full Text PDFSirolimus-associated regression of benign lymphangioendothelioma.
J Am Acad Dermatol
November 2014
Department of Dermatology, University of Alabama, Birmingham, Alabama.
Proteinuria after conversion to sirolimus in kidney transplant recipients: impact of pre-existing proteinuria, graft function, and angiotensin-converting enzyme inhibitors/angiotensin-receptor antagonists.
Clin Transplant
February 2011
Klinik für Innere Medizin III, Klinikum der Friedrich-Schiller-Universität, Jena, Germany.
Background: Proteinuria is a known side effect of therapy with sirolimus. The effect of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers (ACEI/ARB ) on sirolimus-associated proteinuria has not yet been assessed.
Patients And Methods: A retrospective cohort study of renal transplant patients treated with sirolimus (n = 55) was performed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!